3 of 100
BACKNEXT
3. Hi-Tech Pharmacal
3-year average
Revenue Growth: 51%
Profit Growth: 234%
Total Return: 42%
This maker of generic drugs for allergies, diabetes and pain reported 51% sales gains in 2010 and has continued strong this year with a 45% year-over-year increase in the most recent quarter. The company-which specializes in liquid and spray drugs and makes a popular generic version of the allergy medication Flonase-seems poised for continued growth: It currently has 13 pending generics applications at the Food & Drug Adminstration, addressing more than $1 billion in name-brand drug sales in 2010, according to IMS Health. Besides its generics division, Hi-Tech has two other segments: The health care products division sells branded over-the-counter products. And a line of magnesium supplements, acquired in 2010, has also contributed to sales.
Get stock quote: HITK
Revenue ($ millions): $190.9
Net Income ($ millions): $41.5
Industry: Health Care
Network with Hi-Tech Pharmacal
What businesses do you think are primed to grow in this economy?
From the September 26, 2011 issue.
Revenue and profit figures reflect the four quarters ended on or before April 30,2011.
Total return is through June 30, 2011.

Sturm Ruger & Co 848%
Cirrus Logic 340%
Hi-Tech Pharmacal 234%
Green Mountain Coffee Roasters 120%
Netflix 116%
Acme Packet 108%
To qualify, a company -- domestic or foreign -- must be trading on a major U.S. stock exchange; file quarterly reports to the SEC; have a minimum market... More
Current Issue
  • Give the gift of Fortune
  • Get the Fortune app
  • Subscribe
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer LIBOR Warning: Neither BBA Enterprises Limited, nor the BBA LIBOR Contributor Banks, nor Reuters, can be held liable for any irregularity or inaccuracy of BBA LIBOR. Disclaimer. Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.